pyrazofurin and Leukemia--Myeloid--Acute

Pyrazofurin was administered to 17 patients with refractory acute myelogenous leukemia in 5-day courses every 2-3 weeks. Doses ranged from 30 to 60 mg/m2/day. Severe stomatitis and dermatitis occurred at doses effective in reducing the leukocyte count (45 mg/m2). Reduction of the dose to 30 mg/m2 resulted in less toxicity and less chemotherapeutic effect. These results indicate that at tolerable doses given as described, pyrazofurin had little antileukemic activity in acute myeologenous leukemia.

Topics: Adult; Aged; Amides; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Eruptions; Drug Evaluation; Female; Humans; Inflammation; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Mucous Membrane; Pyrazoles; Ribonucleosides; Ribose

Topics: Adolescent; Adult; Aged; Amides; Animals; Carcinoma 256, Walker; Cell Division; Cell Line; Female; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Mouth Mucosa; Neoplasms; Orotic Acid; Pyrazoles; Pyrimidine Nucleotides; Ribonucleosides; Ribose; Uridine